Is it reasonable to consider second-line chemotherapy in patients with hormone-refractory prostate cancer?

Abstract

Both second-line treatments, a combination of carboplatin and vinblastine and a monotherapy with docetaxel, showed modest activity at subtoxic doses in patients with HRPC.